| Factor Information | |
|---|---|
| Data ID | 4018 |
| Factor | Surgical or percutaneous intervention |
| Description | N/A |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To investigate the association between plasma levels of NLRP3 and HMGB1 and their prognostic significance in neonatal patients with CHD. |
| p Value | <0.05 |
| Conclusion | Compared with the patients that survived, the deceased patients showed significantly higher plasma levels of NLRP3, HMGB1 and NT-pro-BNP (P < 0.01). Neonatal patients with CHD and a poor prognosis had higher NLRP3 and HMGB1 levels, which suggests that these might be potential biomarkers of CHD prognosis |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 31852352 |
| Year | 2019 |
| Title | NOD-like receptor protein 3 and high mobility group box-are associated with prognosis of patients with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | neonates | |
| Source | patients | |
| Region | Hangzhou, China | |
| Method | immunosorbent assay | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | Surgical or percutaneous intervention | |
| Group | low HMGB1 group(Treatment) | high HMGB1 group(Control) |
| Number | 13 | 27 |
| Age | < 3 years old | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 0.317 | 0.628 |
